FIND THE OPPORTUNITY. MAKE THE DEAL. GET TO MARKETNewport Premium(for Generics) is the most advanced product targeting, global business development and API sourcing system from the industry authority on the global generics market.Created specically for demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, it can help you to identify and evaluate new product development and licensing opportunities ahead of the competition.Unique strategic intelligence and powerful competitive analysis. It integrates intelligence on more than 60,000 launched products containing over 10,000 different active ingredients and over 30,000 corporate groups.With its sophisticated targeting capabilities, Newport Premium (for Generics) can help you indentify promising new partner companies and secure early, exclusive sources of API supply. API consumption data and trends can be included in product-targeting searches, enabling you to nd the most appropriate business opportunities quickly and accurately.Test and explore new business strategies, recognize potential barriers to market entry, and plan your development pipeline effectively. With the industrys most sophisticated product targeting capabilities, it can signicantly enhance your competitive edge.CONSOLIDATED DATA ON GENERICSPatent expirationParagraph IV dataPatent constraintsMarket sizeSales volume, consumption and pricingMarket leads for potential partners/acquisition targetsRegion-specic dataCompetitor intelligenceWHO CANBENEFITStrategic planningBusiness developmentProduct developmentAPI sourcing and salesProduct intelligenceCompany intelligenceNEWPORT PREMIUM (FOR GENERICS) POWERFUL INTEGRATED API INTELLIGENCE WITH UNIQUE ANALYSISSTRATEGIC PLANNINGEvaluate new product developmentopportunities in over 70 markets worldwide including India and ChinaIdentify niche opportunities that match your strategic needs and unique research, sales or marketing strengthsAdjust your research timing, priorities and resources based on active competitive intelligence monitoringTarget products using over 40 different criteria, covering patents, product characteristics, sales trends, and active ingredient availabilityProduct prole pages summarize all key product-related data, from sales to exclusivitiesWeekly alerting on commentaries covering paragraph IV patent challenges on several hundred productsTHOMSON REUTERS REGIONAL OFFICESNorth AmericaPhiladelphia+1 800 336 4474+1 215 386 0100Latin America+55 11 8370 9845Europe, Middle East and Africa London+44 20 7433 4000Asia Pacic Singapore+65 6775 5088Tokyo+81 3 5218 6500For a complete ofce list visit:science.thomsonreuters.com/contactLS 201209 1004542 Copyright 2013 Thomson ReutersNEWPORT PREMIUM (FOR GENERICS)BUSINESS DEVELOPMENTProle competitors, business partners, and candidate products for acquisition, alliances, licensing, or supply and manufacturingTrack and monitor the launch, API development and patenting activities of competitors worldwide, including India and ChinaEvaluate candidate products against the earliest competitive intelligenceAPI SOURCING AND SALESRecognize critical patent, exclusivity and regulatory issues with candidate productsAnalyze and compare API consumption data and trends by region, and by dose form for the current and previous yearDiscover early, exclusive sources of API supplyAnalyze routes of synthesis together with required intermediates and reagents, in addition to the referenced patents and scientic literaturePRODUCT INTELLIGENCEMarket size and sales volume dataUnique, early API manufacturing intelligence for 10,000 active ingredientsRegulatory lings, such as US, Japanese and Korean DMFs, Certicates of Suitability, Indian and Chinese Import Registrations and US DEA registration noticesTwo years of regional sales and consumption data, worldwide launch, and pack price data for 60,000 launched products containing over 10,000 different active ingredientsUS market share breakdown by dose form and strengthUS Orange Book, EU centralized procedure, and European rst market authorization data Chemical structure diagrams for thousands of productsRoutes of synthesis, including intermediates and reagents with patent and literature references for over 3,000 productsPowerful indexing and searching of products according to FDA approved indication and technology classProprietary analyticsGMP Certications by ANVISA & WHOUS DMF Generic Drug User Fee reference statusCOMPANY INTELLIGENCECompetitor proles of over 50,000 companies and corporate groups, including subsidiaries, nished dose launches, US approvals, regulatory lings, APIs manufactured, inspections by the US FDA and other regulatory agencies and Warning LettersDetailed manufacturing capabilities for over 1,200 API and biologic manufacturing sites and more than 600 contract dose manufacturing sites.Company key nancial indicators and sales forecastsProprietary company ratingsPATENTSWorldwide patent families and individual patents for more than 90 countriesComprehensive Supplementary Protection Certicate (SPC) data for EuropeProjected loss of exclusivity dates for US, European, Japanese and South Korean marketsParagraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 400 products.CURRENT AWARENESSE-mail alerting on key changes in products and companies, including new regulatory lings, approvals, and patent challengesReal-time news regarding products and companiesReports on key conferences covering the generics industrySee which manufacturers are involved in producing or developing a particular API and what stage they have reachedLEARN MORETo learn more about Newport Premium (for Generics), including the additional modules for Phase III drugs,Generic industry deals (including mergers and acquisitions), US Market Shares, and Biologics, visit go.thomsonreuters.com/newport.